Stockscreener 앱 받기
21.76
0.41%
-0.09
시간 외 거래:
21.18
-0.58
-2.67%
전일 마감가:
$21.85
열려 있는:
$21.42
하루 거래량:
494.02K
Relative Volume:
1.02
시가총액:
$1.58B
수익:
$384.10M
순이익/손실:
$-9.07M
주가수익비율:
-155.43
EPS:
-0.14
순현금흐름:
$11.10M
1주 성능:
-6.85%
1개월 성능:
+1.40%
6개월 성능:
-10.42%
1년 성능:
+19.30%
1일 변동 폭
$21.32
$21.79
1주일 범위
$21.32
$23.38
52주 변동 폭
$16.56
$28.15
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
명칭
Kiniksa Pharmaceuticals International Plc
전화
(781) 431-9100
주소
23 OLD BOND STREET, FLOOR 3, LONDON
KNSA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KNSA
Kiniksa Pharmaceuticals International Plc
|
21.76 | 1.58B | 384.10M | -9.07M | 11.10M | -0.14 |
|
ZTS
Zoetis Inc
|
159.61 | 71.47B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.19 | 47.98B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.45 | 47.20B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
14.85 | 17.02B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
307.36 | 13.80B | 2.76B | 1.11B | 898.10M | 22.77 |
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2024-09-13 | 개시 | Jefferies | Buy |
| 2024-05-03 | 개시 | Wells Fargo | Overweight |
| 2020-06-29 | 재확인 | BofA Securities | Buy |
| 2020-04-01 | 개시 | BofA/Merrill | Buy |
| 2019-03-11 | 개시 | Barclays | Overweight |
| 2018-12-12 | 재확인 | Wedbush | Outperform |
| 2018-06-19 | 개시 | JMP Securities | Mkt Outperform |
모두보기
Kiniksa Pharmaceuticals International Plc 주식(KNSA)의 최신 뉴스
Kiniksa CFO Mark Ragosa sells shares worth $368,465 By Investing.com - Investing.com South Africa
Kiniksa CFO Mark Ragosa sells shares worth $368,465 - Investing.com India
Kiniksa pharmaceuticals CFO Mark Ragosa sells $469,923 in stock By Investing.com - Investing.com South Africa
Kiniksa pharmaceuticals CFO Mark Ragosa sells $469,923 in stock - Investing.com
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Earns Buy Rating from Analysts at Citigroup - MarketBeat
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CAO Michael R. Megna Sells 9,051 Shares - MarketBeat
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Receives $36.60 Average Target Price from Analysts - MarketBeat
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CFO Sells $809,277.00 in Stock - MarketBeat
Globeflex Capital L P Boosts Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Sells 17,118 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) - MarketBeat
Kiniksa Pharmaceuticals CFO Mark Ragosa sells $809k in shares By Investing.com - Investing.com Canada
Kiniksa Pharmaceuticals CAO Michael Megna sells shares worth $203,194 By Investing.com - Investing.com Australia
Kiniksa Pharmaceuticals CAO Michael Megna sells shares worth $203,194 - Investing.com India
Kiniksa Pharmaceuticals CFO Mark Ragosa sells $809k in shares - Investing.com
Kiniksa Pharmaceuticals Executives Sell Shares - TradingView
3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now - Mitrade
3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now - The Motley Fool
Taking on analysts’ expectations and winning: Kiniksa Pharmaceuticals International Plc (KNSA) - SETE News
Citigroup Initiates Coverage on Kiniksa Pharmaceuticals International With Buy Rating, $40 Price Target - Marketscreener.com
Kiniksa Pharmaceuticals COO sells shares worth $261,333 - Investing.com
Kiniksa Pharmaceuticals COO sells shares worth $261,333 By Investing.com - Investing.com UK
Deeper Dive: Understanding Kiniksa Pharmaceuticals International Plc (KNSA) Through its Various Ratios - The Dwinnex
Kiniksa Pharmaceuticals Stock Is Attractive From Valuation Perspective-JP Morgan Analyst - Benzinga
Is Kiniksa Pharmaceuticals International, plc (KNSA) the Best UK Growth Stock to Buy Now? - Insider Monkey
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Sold by Rhumbline Advisers - Defense World
New York State Common Retirement Fund Has $302,000 Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) - Defense World
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Sees Large Increase in Short Interest - Defense World
10 Best UK Growth Stocks to Buy Now - Insider Monkey
Is Kiniksa Pharmaceuticals International, plc (KNSA) the Best Small Cap Pharma Stocks to Buy Now? - Insider Monkey
Is Kiniksa Pharmaceuticals International, plc (KNSA) the Best Small Cap Pharma Stock to Buy Now? - Yahoo Finance
12 Best Small Cap Pharma Stocks to Buy Now - Insider Monkey
Decoding Kiniksa Pharmaceuticals International PLC (KNSA): A Str - GuruFocus.com
Kiniksa Pharmaceuticals Shifts Strategic Focus with Key Agreement Terminations and 2024 Financial Results - Defense World
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q4 2024 Earnings Call Transcript - Insider Monkey
Kiniksa Pharmaceuticals Q4 2024 Earnings: Revenue at $122.5M, Mi - GuruFocus.com
Kiniksa issues updates on abiprubart, KPL-387, mavrilimumab - MSN
Big Pipeline Updates From Kiniksa Pharmaceuticals (NASDAQ:KNSA) - Seeking Alpha
Kiniksa to launch Phase 2/3 trial for heart drug KPL-387 - Investing.com India
Kiniksa Pharmaceuticals Swings to Q4 Loss, Revenue Increases -February 25, 2025 at 08:20 am EST - Marketscreener.com
Kiniksa to launch Phase 2/3 trial for heart drug KPL-387 By Investing.com - Investing.com South Africa
Earnings Flash (KNSA) Kiniksa Pharmaceuticals Posts Q4 Total Revenue $122.5M, vs. FactSet Est of $123.4M - Marketscreener.com
Earnings Flash (KNSA) Kiniksa Pharmaceuticals Posts Q4 Net Loss $-0.12 a Share, vs. FactSet Est of $-0.06 Loss - Marketscreener.com
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution - The Manila Times
Kiniksa Pharmaceuticals Reports Strong Q4 2024 Financials with ARCALYST Revenue of $417 Million and Anticipates 2025 Sales Growth - Nasdaq
Kiniksa Pharmaceuticals Announces Development of KPL-387 in - GlobeNewswire
Can Kiniksa's 79% Revenue Surge Continue as Company Shifts Pipeline Focus? - StockTitan
Can Kiniksa's New Pericarditis Drug Build on Its $800M ARCALYST Success? - StockTitan
KNSAKiniksa Pharmaceuticals International, plc Latest Stock News & Market Updates - StockTitan
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 - GlobeNewswire
Kiniksa Pharmaceuticals COO Tessari Eben sells $273,980 in shares - MSN
Kiniksa Pharmaceuticals COO sells shares worth $273,980 - MSN
Kiniksa Pharmaceuticals International Plc (KNSA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
9.75%
자본화:
|
볼륨(24시간):